The FDA recently announced a new label requirement for prescription opioids and medications that treat opioid use disorder (OUD).
Earlier this year, the FDA approved Invokana to reduce late-stage kidney disease and improve cardiovascular health in patients living with Type 2 diabetes and diabetic kidney disease. However, lawsuits dating back to 2015 indicate adverse cardiovascular events like heart attacks may be a side effect for certain patients.
A study from the National Safety Council indicates that more Americans die from opioids than car accidents. However, recent research indicates opioid usage may influence car fatality rates, particularly as drunk driving accidents have been on a gradual decline over the past 20 years.
The US Food and Drug Administration (FDA) recently approved a safety label change for a class of type 2 diabetes medicines called sodium-glucose transporter 2 (SGLT2) inhibitors. These drugs may lead to an increased risk of diabetic ketoacidosis, blood, kidney and serious urinary tract infections.
In September 2019, Purdue Pharma reached an agreement to settle the large number of pending claims against their company. Purdue and its subsidiaries decided to file for Chapter 11 bankruptcy, which will help restructure the company, remove the company’s founding family and restrict where and how Purdue Pharma can do business moving forward.